Payment overview · 2025
General Payments
$233.71
6 reported records · 4 companies
Healthcare provider profile · identity verified
John C. Tuttle, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NOBLESVILLE, IN · NPI 1194712877
Verified facts
What the public records show
CMS Open Payments records show John C. Tuttle, MD received $233.71 in general payments during 2025 across 6 reported records.
Inari Medical, Inc. accounted for 60.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $141.73 | 60.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.30 | 16.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.44 | 16.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.24 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.71 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $141.73 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $141.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 96 |
| Omeprazole | Omeprazole | 318 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 313 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 75 |
| Lisinopril | Lisinopril | 266 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 68 |
| Gabapentin | Gabapentin | 217 | 50 |
| Losartan Potassium | Losartan Potassium | 215 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 45 |
| Eliquis | Apixaban | 185 | 38 |
| Metformin Hcl Er | Metformin Hcl | 175 | 44 |
| Trazodone Hcl | Trazodone Hcl | 160 | 41 |
| Clonazepam | Clonazepam | 159 | 25 |
| Alprazolam | Alprazolam | 152 | 31 |
| Spironolactone | Spironolactone | 150 | 33 |
| Simvastatin | Simvastatin | 144 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 32 |
| Montelukast Sodium | Montelukast Sodium | 139 | 36 |
| Ozempic | Semaglutide | 137 | 25 |
| Pregabalin | Pregabalin | 137 | 27 |
| Mounjaro | Tirzepatide | 132 | 14 |
| Jardiance | Empagliflozin | 130 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 32 |
| Potassium Chloride | Potassium Chloride | 123 | 27 |
| Irbesartan | Irbesartan | 120 | 30 |
| Carvedilol | Carvedilol | 119 | 34 |
| Sertraline Hcl | Sertraline Hcl | 118 | 30 |
| Meloxicam | Meloxicam | 116 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 31 |
| Tramadol Hcl | Tramadol Hcl | 110 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 20 |
| Torsemide | Torsemide | 105 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 32 |
| Ezetimibe | Ezetimibe | 103 | 28 |
| Metformin Hcl | Metformin Hcl | 103 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 24 |
| Lorazepam | Lorazepam | 88 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 36 |
| Alendronate Sodium | Alendronate Sodium | 83 | 26 |
| Prednisone | Prednisone | 83 | 49 |
| Methylprednisolone | Methylprednisolone | 81 | 74 |
| Celecoxib | Celecoxib | 79 | 20 |
| Glimepiride | Glimepiride | 72 | 20 |
| Ondansetron Odt | Ondansetron | 72 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 16 |
| Fenofibrate | Fenofibrate | 71 | 19 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Allopurinol | Allopurinol | 63 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 14 |
| Furosemide | Furosemide | 62 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 22 |
| Trulicity | Dulaglutide | 61 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 13 |
| Famotidine | Famotidine | 58 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 18 |
| Gemtesa | Vibegron | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 12 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Baclofen | Baclofen | 41 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 12 |
| Valsartan | Valsartan | 41 | 12 |
| Morphine Sulfate | Morphine Sulfate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Estradiol | Estradiol | 37 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Finasteride | Finasteride | 31 | 12 |
| Nabumetone | Nabumetone | 31 | 11 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Savella | Milnacipran Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Etodolac | Etodolac | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233.71 · 6 records | Inari Medical, Inc. | CT THROMBECTOMY SYSTEM KIT, EVENITY, FLOWTRIEVER CATHETER, S, PROLIA, QULIPTA, UBRELVY, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error